Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Core-binding factor acute myeloid leukemia accounts for 10-15% of AML and is categorized as
favorable-risk AML. However, the 5-year CIR was up to 40% in this group of patients. Emerging
data show that a high frequency of mutations and/or high expression of KIT in CBF AML.
Sorafenib is a multitargeted TKI, thus the purpose of this study is to evaluate the safety
and efficacy of sorafenib combined with standard therapy in CBF AML.
Phase:
Phase 2
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Guangzhou First People's Hospital Guangzhou Panyu Central Hospital Institute of Hematology & Blood Diseases Hospital Peking University People's Hospital Shenzhen Hospital of Southern Medical University Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University